{"title":"来自II期临床试验的分析,Alvelestat, NE(中性粒细胞弹性酶)抑制剂治疗AATD-LD:生物标志物反应(Desmosine和Aa-val360)与临床结果(SGRQ)的相关性","authors":"J. Parkin, S. Rabbie, I. Black, J. Inshaw","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":205419,"journal":{"name":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val360) and Clinical Outcome (SGRQ)\",\"authors\":\"J. Parkin, S. Rabbie, I. Black, J. Inshaw\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":205419,\"journal\":{\"name\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"volume\":\"38 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val360) and Clinical Outcome (SGRQ)